(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
2 days till quarter result
(bmo 2024-05-06)
Expected move: +/- 11.34%
@ $75.22
发出时间: 4 May 2024 @ 03:47
回报率: -0.56%
上一信号: May 4 - 01:22
上一信号:
回报率: 0.98 %
Live Chart Being Loaded With Signals
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States...
Stats | |
---|---|
今日成交量 | 760 943 |
平均成交量 | 720 716 |
市值 | 3.54B |
EPS | $0 ( 2024-02-20 ) |
下一个收益日期 | ( $-1.200 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.19 |
ATR14 | $1.960 (2.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Jacobson Mark L. | Buy | 24 662 | Common Stock |
2024-04-01 | Jacobson Mark L. | Sell | 24 662 | Stock Option (Right to Buy) |
2024-04-01 | Jacobson Mark L. | Sell | 24 662 | Common Stock |
2024-03-14 | Jeffs Roger | Buy | 16 976 | Common Stock |
2024-03-14 | Jeffs Roger | Buy | 13 000 | Common Stock |
INSIDER POWER |
---|
55.22 |
Last 99 transactions |
Buy: 2 269 939 | Sell: 680 650 |
音量 相关性
Axsome Therapeutics Inc 相关性 - 货币/商品
Axsome Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $270.60M |
毛利润: | $237.70M (87.84 %) |
EPS: | $-5.27 |
FY | 2023 |
营收: | $270.60M |
毛利润: | $237.70M (87.84 %) |
EPS: | $-5.27 |
FY | 2022 |
营收: | $50.04M |
毛利润: | $44.84M (89.61 %) |
EPS: | $-4.86 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.47 |
Financial Reports:
No articles found.
Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。